Protocol Ledger

NCT07413939 · Phase II/III · RECRUITING

RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

Interventional Phase II/III clinical trial protocol NCT07413939 sponsored by Roche / Genentech in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-05-21 Enrollment: 650 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07413939
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)650 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07413939
Protocol FieldVerified Registry Value
NCT IdentifierNCT07413939
Consolidated Lead SponsorRoche / Genentech
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment650 participants (ESTIMATED)
Registered Start Date2026-05-21
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07413939
Hospital Research SiteLocationSite Profile
UC Davis Comprehensive Cancer CenterSacramento, CAOpen Hospital Dossier ->
UCSF Medical Center and Helen Diller Cancer CenterSan Francisco, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI